Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pathology|May 16, 2019
Pathological review of primary cutaneous malignant melanoma by a specialist skin cancer multidisciplinary team improves patient care in the UKBevin Bhoyrul, Geoffrey Brent, Faye Elliott, et al.
Melanoma Research|May 20, 2016
Psychosocial, clinical and demographic features related to worry in patients with melanomaZoe Rogers, Faye Elliott, Nadine A Kasparian, et al.
BMC Medical Genetics|July 22, 2008
Analysis of variants in DNA damage signalling genes in bladder cancerAnanya Choudhury, Faye Elliott, Mark M Iles, et al.
Rheumatology Advances in Practice|November 30, 2023
Common co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK BiobankCharikleia Chatzigeorgiou, John C Taylor, Faye Elliott, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 15, 2013
Do vitamin A serum levels moderate outcome or the protective effect of vitamin D on outcome from malignant melanoma?Sinead Field, Faye Elliott, Juliette Randerson-Moor, et al.
Cochrane Evidence Synthesis and Methods|June 6, 2025
Surgical excision methods for skin cancer involving the nail unit: A systematic reviewClaire M Hardie, Ryckie G Wade, Justin C R Wormald, et al.
The Journal of Investigative Dermatology|March 9, 2007
Sun-protective behaviors in families at increased risk of melanomaJulia A Newton Bishop, Tamara Taylor, Henry W W Potts, et al.
BMC Medical Genetics|June 22, 2011
Functional assays to determine the significance of two common XPC 3'UTR variants found in bladder cancer patientsBoling Qiao, Gina B Scott, Faye Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trialSusan D Richman, Matthew T Seymour, Philip Chambers, et al.
JAMA Oncology|February 13, 2016
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal CancerJenny F Seligmann, Faye Elliott, Susan D Richman, et al.
Pageof 5